SCHEMBL2463663

SCHEMBL2463663

Cc1nc(N)c2ncn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3S)c2n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 6/20 0.72
CA5A P35218 1/20 0.66
P2RY1 P47900 6/20 0.61
P2RY11 Q96G91 5/20 0.61
DNPH1 O43598 1/20 0.61
PRKAB2 O43741 1/20 0.61
TRPM2 O94759 1/20 0.61
LDHA P00338 1/20 0.61
ADRB2 P07550 1/20 0.61
FBP1 P09467 1/20 0.61
SRC P12931 1/20 0.61
ADORA1 P30542 1/20 0.61
P2RY2 P41231 1/20 0.61
PRKAG1 P54619 1/20 0.61
PRKAA2 P54646 1/20 0.61
PDE4D Q08499 1/20 0.61
KCNH2 Q12809 1/20 0.61
PRKAA1 Q13131 1/20 0.61
PDE3A Q14432 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29494944 1.00 RNASEL (0.72) RNASELCA5AP2RY1P2RY11DNPH1
SCHEMBL29814022 0.96 RNASEL (0.67) RNASELCA5AP2RY1P2RY11DNPH1
SCHEMBL16700308 0.96 RNASEL (0.67) RNASELCA5AP2RY1P2RY11DNPH1
Water SCHEMBL31186262 0.95 RNASEL (0.66) RNASELCA5AP2RY1P2RY11DNPH1
SCHEMBL30047050 0.93 RNASEL (0.75) RNASELP2RY1P2RY11P2RX3ENPP1
SCHEMBL195866 0.93 RNASEL (0.75) RNASELP2RY1P2RY11P2RX3ENPP1
SCHEMBL2020893 0.92 RNASEL (0.77) RNASELP2RY1P2RY11SRCP2RY2
SCHEMBL20266295 0.92 RNASEL (0.61) RNASELCA5AP2RY1NT5EP2RY12
SCHEMBL30969952 0.92 RNASEL (0.61) RNASELCA5AP2RY1NT5EP2RY12
SCHEMBL29450811 0.91 RNASEL (0.85) RNASELCA5AP2RY1P2RY11DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940470-B1 APPARATUS FOR TESTING PLATELET AGGREGATION IN RESPONSE TO A DRUG UNIV KOREA RES & BUS FOUND (KR) 2020-03-25 EP claimed
US-20190209594-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 2019-07-11 US claimed
EP-3452092-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2019-03-13 EP claimed
CN-104884954-B Test the device and method of the multi-functional and drug response of the blood platelet based on centrifugal type microfludic method 高丽大学校产学协力团 2018-07-24 CN claimed
US-9983220-B2 Apparatus and method for platelet function and drug response testing based on microfluidic chip KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2018-05-29 US claimed
US-9927425-B2 Apparatus and method for testing multi-function and drug response of centrifugal microfluidic-based platelets KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2018-03-27 US claimed
WO-2017191300-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-11-09 WO claimed
US-9759730-B2 Method and device for the determination of platelet function under flow conditions SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) 2017-09-12 US claimed
EP-2645932-B1 BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT BECTON DICKINSON CO (US) 2016-03-02 EP claimed
US-20150355167-A1 APPARATUS AND METHOD FOR TESTING MULTI-FUNCTION AND DRUG RESPONSE OF CENTRIFUGAL MICROFLUIDIC-BASED PLATELETS KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2015-12-10 US claimed
US-8895259-B2 Method for determination of platelet function under flow conditions SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) 2014-11-25 US claimed
EP-1850134-B1 Method and Apparatus for the determination of the Thromboyte function and flow conditions SIEMENS HEALTHCARE DIAGNOSTICS (DE) 2013-01-30 EP claimed
US-20120149004-A1 BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT BECTON, DICKINSON AND COMPANY (US) 2012-06-14 US claimed
EP-1850135-B1 Method for determining the thrombocyte function and flow conditions SIEMENS HEALTHCARE DIAGNOSTICS (DE) 2010-11-03 EP claimed
US-20070254324-A1 Method for determination of platelet function under flow conditions DADE BEHRING MARBURG GMBH 2007-11-01 US claimed
US-20070254325-A1 Method and device for the determination of platelet function under flow conditions DADE BEHRING MARBURG GMBH 2007-11-01 US claimed
EP-1850134-A1 Method and Apparatus for the determination of the Thromboyte function and flow conditions Dade Behring Marburg GmbH (DE) 2007-10-31 EP claimed
WO-2005079250-A2 PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM CORNELL RESEARCH FOUNDATION, INC. (US) 2005-09-01 WO claimed
US-20050181503-A1 Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-08-18 US claimed
US-20050053612-A1 Nucleotide regulation of immune responses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-03-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050053612-A1 Nucleotide regulation of immune responses NT5C2, ENTPD5, ENTPD1 RNASEL 664/4885CA5A 3820/4885P2RY1 7/4885
US-20120149004-A1 BLOOD COLLECTION DEVICES CONTAINING BLOOD STABILIZATION AGENT FUCA2, HBG1, FUT6 RNASEL 682/4885CA5A 4748/4885P2RY1 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.